Suppr超能文献

接受CROSS或FLOT治疗患者的血液学和营养预后生物标志物。

Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT.

作者信息

McNamee Nicholas, Nindra Udit, Shahnam Adel, Yoon Robert, Asghari Ray, Ng Weng, Karikios Deme, Wong Mark

机构信息

Department of Medical Oncology, Westmead Hospital, Sydney, Australia.

Department of Medical Oncology, Liverpool Hospital, Sydney, Australia.

出版信息

J Gastrointest Oncol. 2023 Apr 29;14(2):494-503. doi: 10.21037/jgo-22-886. Epub 2023 Mar 16.

Abstract

BACKGROUND

Neoadjuvant carboplatin and paclitaxel with radiotherapy (CROSS) and perioperative docetaxel, oxaliplatin, calcium folinate and fluorouracil (FLOT) are widely used for gastric (GC), gastro-oesophageal junction (GOJ) and oesophageal cancers (OC). Prognostic and predictive markers for response and survival outcomes are lacking. This study evaluates dynamic neutrophil-lymphocyte ratios (NLR), platelet-lymphocyte ratios (PLR), albumin and body mass index (BMI) as predictors of survival, response and toxicity.

METHODS

This multi-centre retrospective observational study across 5 Sydney hospitals included patients receiving CROSS or FLOT from 2015 to 2021. Haematological results and BMI were recorded at baseline and pre-operatively, and after adjuvant treatment for FLOT. Toxicities were also recorded. An NLR ≥2 and PLR ≥200 was used to stratify patients. Univariate and multivariate analyses were performed to determine predictors of overall survival (OS), disease free survival (DFS), rates of pathological complete response (pCR) and toxicity.

RESULTS

One hundred sixty-eight patients were included (95 FLOT, 73 FLOT). A baseline NLR ≥2 was predictive for worse DFS (HR 2.78, 95% CI: 1.41-5.50, P<0.01) and OS (HR 2.90, 95% CI: 1.48-5.67, P<0.01). Sustained elevation in NLR was predictive for DFS (HR 1.54, 95% CI: 1.08-2.17, P=0.01) and OS (HR 1.65, 95% CI: 1.17-2.33, P<0.01). An NLR ≥2 correlated with worse pCR rates (16% for NLR ≥2, 48% for NLR <2, P=0.04). A baseline serum albumin <33 was predictive of worse DFS and OS with a HR of 6.17 (P=0.01) and 4.66 (P=0.01) respectively. Baseline PLR, BMI, and dynamic changes in these markers were not associated with DFS, OS or pCR rates. There was no association of the aforementioned variables with toxicity.

CONCLUSIONS

This demonstrates that a high inflammatory state represented by an NLR ≥2, both at baseline and sustained, is prognostic and predictive of response in patients receiving FLOT or CROSS. Baseline hypoalbuminaemia is predictive of poorer outcomes.

摘要

背景

新辅助卡铂和紫杉醇联合放疗(CROSS方案)以及围手术期多西他赛、奥沙利铂、亚叶酸钙和氟尿嘧啶(FLOT方案)广泛用于胃癌(GC)、胃食管交界癌(GOJ)和食管癌(OC)。目前缺乏反应和生存结果的预后及预测标志物。本研究评估动态中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、白蛋白和体重指数(BMI)作为生存、反应和毒性的预测指标。

方法

这项在悉尼5家医院开展的多中心回顾性观察研究纳入了2015年至2021年接受CROSS或FLOT方案治疗的患者。在基线、术前以及FLOT方案辅助治疗后记录血液学结果和BMI。同时记录毒性反应。采用NLR≥2和PLR≥200对患者进行分层。进行单因素和多因素分析以确定总生存(OS)、无病生存(DFS)、病理完全缓解(pCR)率和毒性的预测因素。

结果

共纳入168例患者(95例接受FLOT方案,73例接受CROSS方案)。基线NLR≥2可预测较差的DFS(风险比[HR]2.78,95%置信区间[CI]:1.41 - 5.50,P<0.01)和OS(HR 2.90,95% CI:1.48 - 5.67,P<0.01)。NLR持续升高可预测DFS(HR 1.54,95% CI:1.08 - 2.17,P = 0.01)和OS(HR 1.65,95% CI:1.17 - 2.33,P<0.01)。NLR≥2与较差的pCR率相关(NLR≥2组为16%,NLR<2组为48%,P = 0.04)。基线血清白蛋白<33可预测较差的DFS和OS,HR分别为6.17(P = 0.01)和4.66(P = 0.01)。基线PLR、BMI以及这些标志物的动态变化与DFS、OS或pCR率无关。上述变量与毒性反应无关联。

结论

这表明,无论是基线时还是持续存在的以NLR≥2为代表的高炎症状态,对接受FLOT或CROSS方案治疗的患者具有预后意义且可预测反应。基线低白蛋白血症预示预后较差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa91/10186526/8937a482e2d5/jgo-14-02-494-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验